Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Treatment of severe psoriasis with infliximab

Authors JA Leman, AD Burden

Published 5 December 2008 Volume 2008:4(6) Pages 1165—1175

DOI https://doi.org/10.2147/TCRM.S3094

Review by Single-blind

Peer reviewer comments 2

JA Leman, AD Burden

Alan Lyell Centre for Dermatology, Western Infirmary, Glasgow, UK

Abstract: Psoriasis is a chronic, immune mediated inflammatory disease characterized by increased cell signalling via cytokines and chemokines on a background of up-regulated gene expression. There is substantial evidence that psoriasis should be regarded as more than a cutaneous disease; major psychological morbidity and increased mortality from cardiovascular disease and cancer are increasingly recognized. Improved understanding of the genetic and immunological mechanisms underpinning psoriasis has occurred concurrently with the development of targeted biological therapies including infliximab. These newer therapeutic approaches can be very effective but their long term safety profile is not yet fully determined.

Keywords: psoriasis, pathogenesis, co-morbidities, treatment, infliximab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

The influence of bile salt on the chemotherapeutic response of docetaxel-loaded thermosensitive nanomicelles

Kim DW, Ramasamy T, Choi JY, Kim JH, Yong CS, Kim JO, Choi HG

International Journal of Nanomedicine 2014, 9:3815-3824

Published Date: 8 August 2014

Biological augmentation of rotator cuff repair using bFGF-loaded electrospun poly(lactide-co-glycolide) fibrous membranes

Zhao S, Zhao J, Dong S, Huangfu X, Li B, Yang H, Zhao J, Cui W

International Journal of Nanomedicine 2014, 9:2373-2385

Published Date: 14 May 2014

Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

Bramlage P, Deutsch C, Krüger R, Wolf A, Müller P, Zwingers T, Beime B, Mengden T

Vascular Health and Risk Management 2014, 10:303-309

Published Date: 13 May 2014

Erratum

Sørensen HT, Friborg S, Rungby J, Christiansen JS, Vaag A, Beck-Nielsen H

Clinical Epidemiology 2012, 4:49-50

Published Date: 20 December 2012

Corrigendum

Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012

Magnetic nanoparticles for gene and drug delivery

Stuart C McBain, Humphrey HP Yiu, Jon Dobson

International Journal of Nanomedicine 2008, 3:169-180

Published Date: 6 June 2008

RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker ανβ3 integrin with MR T1 mapping

Tianyi Ke, Eun-Kee Jeong, Xuli Wang, Yi Feng, Dennis L Parker, Zheng-Rong Lu

International Journal of Nanomedicine 2007, 2:191-199

Published Date: 15 July 2007